<a href="https://laohu8.com/S/AEON">AEON Biopharma</a> Announces Private Placement of Shares and Warrants
AEON Biopharma Inc. has announced a private placement involving the sale of its Class A common stock, pre-funded warrants, and additional warrants to certain investors. The securities are being offered at a purchase price of $0.9116 per share, or $0.9115 per pre-funded warrant. The first closing of the private placement is expected to take place the week of November 17, 2025, with the company planning to issue and sell 1,964,905 shares or pre-funded warrants. A second closing, subject to stockholder approval and other customary conditions, is expected to follow, involving the sale of an additional 4,616,924 shares or pre-funded warrants and 6,581,829 warrants. These securities are being sold in a private transaction and have not been registered under the Securities Act.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. AEON Biopharma Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001837607-25-000072), on November 13, 2025, and is solely responsible for the information contained therein.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.